She Grew a Virus in Her Lab and Cured Her Own Cancer.. So here is…. The Complete Story of Viral Therapy
Imagine being told your cancer is back. Again. And you can’t face another round of chemo the kind that leaves you weak, bald, and barely able to get out of bed.
Now imagine you’re a virologist. You have access to a lab. And you decide to grow your own cure.
That’s not a movie plot. That’s the true story of Dr. Beata Halassy and it’s changing how the world looks at cancer treatment.
LET’S BREAK THIS DOWN….
· Viral therapy uses viruses to infect and burst cancer cells, then wakes up your immune system to hunt cancer elsewhere.
· Dr. Beata Halassy, a virologist, treated her own recurrent breast cancer with viruses she grew in her lab. Her tumour shrank by 63% and she remains cancer-free years later.
· Two oncolytic viruses are now FDA-approved for melanoma, and trials are showing promise in pancreatic and brain cancers.
· Side effects are much milder than chemo or radiation mostly flu-like symptoms.
· For Kenya, the treatment is not yet routine, but the market and research interest are growing.
Lets talk about Dr. Beata Halassy….The Scientist Who Became Her Own Patient
Dr. Beata Halassy is a virologist at the University of Zagreb in Croatia. In 2016, she was diagnosed with triple-negative breast cancer (TNBC)…which is the most aggressive and deadliest subtype of breast cancer. She had surgery and chemotherapy.
In 2018, it came back. She had surgery again.
Then, in 2020, at age 49, the cancer returned for a third time a 2-centimetre tumour at the site of her previous mastectomy, now invading her skin.
She was out of good options. More chemo? She couldn’t face it.
But she wasn’t just any patient. She had spent decades studying viruses. She knew about oncolytic virotherapy (OVT)….using viruses to kill cancer cells and she knew it had never been approved for breast cancer…
So she decided to try it on herself.
What She Did.. Step By Step…..
Dr. Halassy didn’t just grab any virus. She carefully selected two viruses she had worked with before and that were known to infect the type of cells her tumour came from:
- Measles Virus (Mev)…This the same strain used in childhood vaccines, with a well-established safety record.
- Vesicular stomatitis virus (VSV)… This is a virus that at worst causes mild flu-like symptoms in humans. I am sure you can see where this is going…
She grew both viruses in her own academic laboratory. They were research-grade, not clinical-grade meaning they weren’t manufactured under pharmaceutical standards. But this didn’t stop her…
A colleague administered the injections directly into her tumour over a two-month period… seven injections of measles virus, spaced 3–4 days apart, followed by three injections of VSV. After surgery to remove what was left of the tumour, she received one more measles injection as a preventive measure.
Her oncologists monitored her throughout. If anything went wrong, they were ready to switch her to conventional chemotherapy.
The Results: From 2.47 cm³ to 0.91 cm³
The outcome was remarkable.
In just two months, her tumour shrank from 2.47 cm³ to 0.91 cm³ — a 63% reduction. The tumour changed from a hard, fixed lump with inflamed skin to a soft, movable nodule. Its invasive edges receded, making it far easier for surgeons to remove.
When pathologists examined the removed tumour, they found something even more important…the tumour was completely infiltrated by immune cells. Now before internet doctors attack… let’s be specific:
· CD20-positive B cells jumped from 10% to 70%
· CD8-positive T cells jumped from 30% to 60%
· Macrophage infiltration also increased
· The tumour shifted from PD-L1 negative to PD-L1 positive meaning it became a target for immunotherapy
In plain English for simply sake…. the viruses didn’t just kill cancer cells directly. They woke up her immune system and turned the tumour into a battlefield. Her body’s own defences joined the fight. Meaning the barrier the cancer cells had created to protect themselves was broken down… the way Gen Zs did to parliament and ate waheshimiwa food.
She experienced no severe side effects. Just some mild flu-like symptoms. Years later, she remains cancer-free.
So… How Does Viral Therapy Actually Work?
This is the part that sounds like science fiction. Let’s break it down into three stages.
Stage 1: The Virus Finds and Enters Cancer Cells
Oncolytic viruses are either naturally occurring or genetically engineered to target cancer cells specifically. Cancer cells often have defective antiviral defences their interferon pathways are broken, or they display unique surface receptors that normal cells don’t have.
Scientists exploit these weaknesses to design viruses that can only replicate inside cancer cells.
Think of it like a key that only fits one lock. The virus circulates through the body, but it can only “unlock” and enter cancer cells. Normal, healthy cells are left alone. Immune system loves this bit about the whole thing unlike chemo.
Stage 2: The Virus Replicates and Bursts the Cancer Cell
Once inside, the virus hijacks the cancer cell’s machinery to make thousands of copies of itself. The cancer cell swells and eventually bursts open a process called oncolysis.
This releases….
· New virus particles that go on to infect neighbouring cancer cells
· Tumour-associated antigens (TAAs)…bits of the cancer cell that the immune system can recognise
· Damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) molecular “danger signals” that scream “INTRUDER!..MWIZIII!!” to the immune system
Stage 3: The Immune System Gets Recruited
This is the most powerful part and the reason viral therapy is considered a form of immunotherapy, not just a direct killer.
The danger signals released when cancer cells burst attract dendritic cells, the “generals” of the immune system. These cells pick up the tumour antigens and present them to CD8+ T cells and CD4+ T cells training them to recognise and attack cancer cells throughout the body…
Activated CD4+ T cells secrete interleukins like IL-2 and IL-12, which further stimulate cytotoxic CD8+ T cells. Natural killer (NK) cells are also activated, releasing IFN-γ and TNF-α.
This means the virus doesn’t just kill the tumour it was injected into. It teaches the immune system to hunt down cancer cells that may have spread elsewhere. This is called the abscopal effect and it’s why viral therapy can potentially tackle metastases far from the injection site.
The virus also modifies the tumour microenvironment (TME)…. the “neighbourhood” around the tumour. Many tumours create a suppressive environment that shuts down immune cells. Oncolytic viruses can reprogramme this environment, making it hostile to cancer and friendly to immune attack.
The result is what scientists call a “hot” tumour… one that’s infiltrated with T cells and ready for immune-mediated clearance.
Here is The Big Breakthroughs: From Melanoma to Pancreatic Cancer
Melanoma: Two FDA-Approved Viruses
- T-VEC (Imlygic)… This was approved in 2015 for melanoma. Real-world data from 2025 showed median overall survival of 35.5 months in heavily pre-treated patients, with a 67% objective response rate and 35% complete responses.
- Tudriqev (RP1) Now this has been approved August 2026 for advanced melanoma that has stopped responding to immunotherapy. In the IGNYTE trial of 140 patients, the objective response rate was 24.2%, with a median duration of response of 14.1 months.
The therapy is a genetically modified herpes simplex virus type 1 (HSV-1) engineered to selectively target and destroy cancer cells. It is administered in combination with nivolumab (Opdivo). The FDA granted accelerated approval based on these results, with the manufacturer required to conduct post-approval studies to verify clinical benefit.
Pancreatic Cancer: The VIRAGE Trial
Pancreatic cancer is one of the deadliest….with 5-year survival below 10%.
The VIRAGE trial tested an oncolytic virus called VCN-01 combined with standard chemotherapy in metastatic pancreatic cancer. Patients who completed four treatment cycles achieved median overall survival of 14.8 months versus 11.6 months with chemo alone a 56% reduction in risk of death.
Median progression-free survival was 11.2 months versus 7.4 months with chemotherapy alone.
The oncolytic adenovirus showed a manageable safety profile, with most serious treatment-related adverse events resolving. The trial met its primary endpoints of overall survival and safety, supporting advancement to larger phase 3 trials. According to information I can gather so far.
Breast Cancer: Dr. Halassy’s Case
Dr. Halassy’s case remains the most dramatic example of viral therapy in breast cancer. She is the reason I wrote this article, I was really impressed by her story and decided to go down the rabbit hole. Because no OVT agent has yet been approved for breast cancer anywhere in the world but her self-experiment is a powerful proof of concept. Having come from Meru where cancer is more prevalent than any other part of Kenya… I have been very interested in cancer information and research and she is my hero.
How Safe Is It? The Side Effects Showdown
This is where viral therapy truly shines.
A comprehensive comparative analysis found that severe side effects (WHO grades 3–4) are simply not observed with oncolytic viruses, while they are seen with all other systemic therapies chemotherapy, targeted therapy, and even CAR-T cell therapy.
In the pancreatic VIRAGE trial, the most common adverse events were manageable and resolved. The safety profile was favorable compared with conventional cytotoxic therapies.
Here’s how it compares…..
· Chemotherapy kills all fast-dividing cells. That means hair loss, nausea, bone marrow suppression, organ damage, and cumulative toxicity. Severe side effects are common.
· Radiation damages DNA in a targeted area. It can cause skin burns, fatigue, and local tissue damage. Severe effects can happen.
· Viral therapy selectively kills cancer cells and activates the immune system. Most patients get flu-like symptoms, fever, fatigue, and injection-site reactions. Severe side effects are rarely observed.
Dr. Halassy’s own case proves that… she experienced no severe side effects from a treatment that would have sent most chemo patients to the hospital.
Now What does This Means for Meru and for Kenya as a whole?
Kenya records approximately 44,000 to 48,000 new cancer cases annually, with over 29,000 to 32,000 annual deaths. Meru hospice last I checked had reported around 2,350ish cancer cases between 2004-2018. I don’t have any recent data but will do in due time. Stomach cancer is the leading cause of death in cancer related deaths in Meru. So what does this mean?
This translates to at least 80 Kenyans dying from cancer every day, while 125 new cases are recorded daily, according to the National Cancer Institute of Kenya (NCIK).
The country currently has more than 100,000 cancer patients undergoing treatment, with about 50,000 new cases diagnosed each year. The most common cancers treated at major facilities include breast, cervical, prostate, and colon cancers. Now this brings a problem of doctors but I wrote about that in my previous article. So kindly check it out.
But here is the good news….the Kenya Oncolytic Virus Therapies Market is growing, driven by rising cancer cases and government initiatives. The Pharmacy and Poisons Board (PPB) regulates these therapies, and partnerships like Bio Usawa and BioVax are working to strengthen local biologics manufacturing with an initial focus on cancer and autoimmune diseases.
The challenges are real… high cost, limited awareness among healthcare providers, and lack of specialised facilities equipped to administer these treatments. The NCIK has also highlighted critical workforce shortages, including an inadequate number of oncologists and a severe shortage of pathologists needed for timely diagnosis. Again I covered this in my previous post.
By despite these hurdles, Kenya’s government is taking steps to improve cancer care. The National Assembly Health Committee has pledged to push for increased funding for the NCIK, with allocations rising from Sh40 million to Sh349 million in recent years. Kenya has also launched a National Cervical Cancer Elimination Action Plan 2026–2030, focusing on HPV vaccination and expanded screening.
For a Kenyan patient today, viral therapy is not yet a routine option. But it’s coming. And stories like Dr. Halassy’s show why it matters.
The Bottom Line….
Is viral therapy the new cure for cancer? Not yet not for every cancer, and not for every patient. It works best for certain cancers… Like melanoma, some pancreatic cases, glioblastoma and often in combination with other treatments. So sorry if I misled you with the headline….
But is it a game-changer? Absolutely. Here’s why:
- Safety profile is dramatically better than chemo or radiation.
- It trains your immune system to fight cancer long-term.
- It’s expanding … from melanoma to pancreatic, brain, breast, and colorectal cancers.
- Two FDA approvals in a decade, with dozens more in trials.
Dr. Halassy’s story is not an invitation to try this at home. She was a trained virologist with a lab, decades of experience, and oncologists monitoring her every step.
But her case is a powerful proof of concept a reminder that sometimes the most feared things in nature can become our strongest allies.
Cancer is scary. But science is catching up. And viruses the very things we fear …might just become one of our strongest weapons…
I am not an expert so I am always happy for any corrections.
Danny’s Desk…